Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types.
Abstract
6576 Background: Patients with essential thrombocythemia (ET) have limited disease-modifying options. This integrated analysis of 182 ET patients from 2 trials evaluated consistency the efficacy of ropeginterferon alfa-2b (ropeg, BESREMi) across treatment lines and examined the impact of ethnicity and molecular subtype on outcomes. Methods: Data were pooled from the phase 3 randomized SURPASS-ET study (ropeg vs anagrelide [ANA] in HU-resistant/intolerant high-risk ET) and the phase 2b single-arm EXCEED-ET study enrolling both treatment-naïve and previously treated patients in North America. Endpoints included durable modified ELN response, hematologic and molecular responses, thrombotic events, and safety. Results: In SURPASS-ET, ropeg achieved a significantly higher durable modified ELN response at months 9 and 12 than ANA (42.9% vs 6.0%; p
Fields of Study & Subjects
Myeloproliferative Neoplasms: Diagnosis and Treatment
Platelet Disorders and Treatments
Complement system in diseases
Publication details
- Journal / source
- Journal of Clinical Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Volume
- 44
- Issue
- 16_suppl
- Pages
- 6576–6576
- Publication date
- 27 May 2026
- Language
- EN